Medication info
Janumet 100/15 mg (Sitagliptin Phosphate, Pioglitazone Hydrochloride)

Janumet 100/15 mg (Sitagliptin Phosphate, Pioglitazone Hydrochloride)

Prescription medicationTablet
Ingredient · strength
Sitagliptin Phosphate Hydrate›128.5mg / 1 tabletPioglitazone Hydrochloride›16.53mg / 1 tablet
Manufacturer / importer
Jinyang Pharmaceutical Co., Ltd.
Appearance
Light orange film-coated tablets in an oblong shape
Packaging
28 tablets/box [14 tablets/PTP x 2]
Approval status
Active

MFDS item code 202302300 · Approved 2023.07.31 · Insurance code 650304550

Summary

Main use
Improvement of glycemic control in patients with type 2 diabetes mellitus
Who uses it
Adults
Adult dosage
This medicine may be administered as 1 tablet once daily, regardless of meals, to patients with type 2 diabetes mellitus receiving concomitant sitagliptin 100mg and pioglitazone 15mg or 30mg. Assessment of renal function is recommended before starting this medicine and periodically during treatment. No dosage adjustment based on renal function is necessary if the estimated glomerular filtration rate (eGFR) is 45 mL/min/1.73m2 or higher. Do not administer this medicine if the estimated glomerular filtration rate (eGFR) is less than 45 mL/min/1.73m2.

Ingredients

Manufacturer
Jinyang Pharmaceutical Co., Ltd.

Efficacy & effects

Improvement of glycemic control in patients with type 2 diabetes mellitus

View approved original text

This medication helps patients with type 2 diabetes to improve blood sugar control more effectively when used in conjunction with diet and exercise. The combination of sitagliptin and pioglitazone aids in improving blood glucose levels, thereby assisting in diabetes management. It is intended to improve blood glucose control through consistent use and lifestyle changes.

Dosage and Administration

Adult dosage

This medicine may be administered as 1 tablet once daily, regardless of meals, to patients with type 2 diabetes mellitus receiving concomitant sitagliptin 100mg and pioglitazone 15mg or 30mg. Assessment of renal function is recommended before starting this medicine and periodically during treatment. No dosage adjustment based on renal function is necessary if the estimated glomerular filtration rate (eGFR) is 45 mL/min/1.73m2 or higher. Do not administer this medicine if the estimated glomerular filtration rate (eGFR) is less than 45 mL/min/1.73m2.

Precautions

This medication contains sitagliptin and pioglitazone, each with specific cautions to be aware of. First, the sitagliptin component may rarely cause serious allergic reactions. Symptoms such as severe skin swelling, rash, difficulty breathing, and anaphylaxis can occur, so if any of these symptoms appear, the medication should be stopped immediately, and a doctor should be consulted. Sitagliptin can also cause acute pancreatitis, an inflammation of the pancreas. Symptoms such as abdominal pain, nausea, and vomiting should prompt immediate medical attention. The pioglitazone component may strain the heart, so patients with existing heart failure or a history of heart failure should not take this medication. During treatment, symptoms of heart failure such as weight gain, swelling, and dyspnea may occur; if these symptoms arise, medical personnel should be notified immediately. This medication should not be given to patients with a history of bladder cancer or current bladder cancer. It should also be avoided by patients with severely impaired kidney or liver function. Women who are pregnant or may become pregnant should not take this medication. Pre-menopausal women should use appropriate contraception since this medication may promote ovulation. Patients should be vigilant for symptoms of hypoglycemia while using this medication, especially when combined with insulin or sulfonylureas, as the risk of hypoglycemia may increase. While taking this medication, if symptoms such as swelling, weight gain, joint pain, skin rash, or blisters occur, medical personnel should be informed immediately. If symptoms of liver dysfunction (fatigue, jaundice, loss of appetite, etc.) present, prompt testing is recommended. Additionally, this medication contains lactose and should not be prescribed for patients with lactose intolerance. Lastly, this medication may interact with other drugs, so if patients are taking any other medications, they must inform their doctor or pharmacist, and regular assessments of kidney and liver function are recommended.

Side effects

  • Anaphylaxis
  • angioedema
  • Stevens-Johnson syndrome
  • acute pancreatitis
  • congestive heart failure
  • weight gain
  • edema
  • hypoglycemia
  • upper respiratory tract infection
  • nasopharyngitis
Show 73 more
  • headache
  • diarrhea
  • abdominal pain
  • nausea
  • constipation
  • rash
  • urticaria
  • cutaneous vasculitis
  • severe and disabling arthralgia
  • vesicular pemphigoid
  • myalgia
  • limb pain
  • back pain
  • interstitial lung disease
  • pruritus
  • thrombocytopenia
  • rhabdomyolysis
  • elevated liver enzymes
  • acute renal failure
  • pneumonia
  • diabetic complications
  • metabolic acidosis
  • falls
  • cardiac arrest
  • dyspepsia
  • dizziness
  • increased serum triglycerides
  • gastritis
  • hyperglycemia
  • loss of appetite
  • upper abdominal pain
  • chest pain
  • fatigue
  • weakness
  • nausea
  • dyspnea
  • itching
  • chest discomfort
  • tremors
  • chills
  • gastrointestinal disease
  • abdominal pain
  • epigastric discomfort
  • paresthesia
  • muscle rigidity
  • head discomfort
  • hepatic disease exacerbation
  • urticaria
  • eczema
  • arthralgia
  • knee abnormalities
  • arm weakness syndrome
  • proteinuria
  • increased serum creatinine
  • anxiety
  • insomnia
  • drowsiness
  • simple herpes
  • visual blurring
  • hypertension
  • heart failure
  • orthostatic hypotension
  • palpitations
  • stroke
  • sexual dysfunction
  • myocardial infarction
  • abdominal pain
  • heart failure
  • reduced vision
  • diabetic macular edema
  • hepatic failure
  • macular edema
  • fracture

Not everyone experiences these, and they can vary from person to person.

Storage

This medication should be stored in a special container that keeps out light and air, and must be kept away from humid areas. To maintain its effectiveness, it is best stored at temperatures between 15 and 30 degrees Celsius.

Appearance and packaging

Appearance

Light orange film-coated tablets in an oblong shape

Package unit

28 tablets/box [14 tablets/PTP x 2]

Same-ingredient medicines

Even with the same ingredient, strength, dosage form and how it is taken can differ.

Even with the same ingredient, the dose and directions can differ by strength and dosage form. Talk to a doctor or pharmacist before switching from a medication you are already taking.

Questions about this medicine

No questions yet.

For anything that needs medical judgment, consult a doctor or pharmacist.

Related searches

Search tags

Suggested searches

This drug information is based on data provided by the Korea Ministry of Food and Drug Safety.
Consult a doctor or pharmacist for accurate dosage, administration, and usage instructions.